DUBLIN, Jan. 14, 2016 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/k4s8p8/global_psoriatic) has announced the addition of the "Global Psoriatic Arthritis Market 2015-2019" report to their offering.
The global market for psoriatic arthritis is expected to witness moderate growth during the forecast period and factors like the increase in penetration of biologic therapies are expected to augment the prospects for growth in this market.
Additionally, the recent launch of products like Otezla and Stelara is also expected to boost market growth during the forecast period, resulting in its moderate CAGR of nearly 5% by 2019.
Some emerging trends are expected to boost the global psoriatic arthritis market. The dominance of the market by biologics in the treatment of psoriatic arthritis patients is one such trend. It is expected that biologics will be the preferred treatment option of the medical profession as well as the patients themselves. This will increase the number of treatment-seeking patients and result in an increase in the overall consumption of drugs for this condition.
According to the report, the global psoriatic arthritis market is driven by several factors. The presence of growing unmet needs for appropriate drugs is one of the major factors propelling the growth of the market.
Further, the report states that many branded drugs present for the treatment of psoriatic arthritis are soon going to lose their patent protection. Expiry of patents results in the loss of exclusivity of that specific drug, leading to a rapid decline in its sales. Therefore, this is expected to have a negative impact on the revenue of the branded drugs used to treat psoriatic arthritis.
Leading vendors in this market are
- Janssen Pharmaceuticals
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Product profiles
Part 04: Market research methodology
Part 05: Introduction
Part 06: Disease overview
Part 07: Pipeline portfolio
Part 08: Novel mechanisms targeted by pipeline candidates
Part 09: Market landscape
Part 10: Market segmentation by MoA
Part 11: Market segmentation by type of molecule
Part 12: Market segmentation by severity of disease
Part 13: Market segmentation by route of administration
Part 14: Market segmentation by dosage form
Part 15: Geographical segmentation
Part 16: Market drivers
Part 17: Impact of drivers
Part 18: Market challenges
Part 19: Impact of drivers and challenges
Part 20: Market trends
Part 21: Vendor landscape
Part 22: Key vendor analysis
For more information visit
Laura Wood, +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets